Biopharma IPOs Sluggish In Q1. Will That Continue?

Published: Apr 14, 2017

The climate seemed right for biotechs to go public at the beginning of 2017. Well, maybe not right, but definitely better than the previous year. Coming out of the annual J.P. Morgan Healthcare Conference in January, there was optimism small drug developers would turn up the heat on initial public offerings (IPOs) after a lukewarm 2016.

Back to news